Actualités

19 avril 2022

Childhood cancer AEs may be under-reported by clinicians

Children undergoing treatment for cancer report significantly more symptomatic adverse events (AEs) than their clinicians but fewer than their caregivers, suggests research comparing assessments for triads of patients, caregivers and clinicians.

Lire >

12 avril 2022

Glycosylation of anti-dsDNA autoantibodies linked to SLE disease activity

Among patients with systemic lupus erythematosus (SLE), glycosylation patterns of anti-double-stranded (ds)DNA immunoglobulin (Ig)G autoantibodies differ from those of total IgG and correlate with disease activity, suggests research published in eBioMedicine.

Lire >

4 avril 2022

Serum NfL could serve as a biomarker in spinocerebellar ataxia type 1

Serum levels of neurofilament light (sNfL) protein are elevated in both the pre-ataxic and ataxic stages of spinocerebellar ataxia type 1 (SCA1), and are associated with onset of ataxia, shows research published in Neurology.

Lire >

28 mars 2022

‘Reassuring’ findings for COVID-19 risks among childhood cancer survivors

Child, adolescent and young adult survivors of childhood cancer do not have a greater risk of COVID-19 infection and severe illness than individuals without a history of cancer, suggest findings from a population-based study published in the Journal of Clinical Oncology.

Lire >

21 mars 2022

Early promise for adeno-associated virus gene therapy in Tay–Sachs disease

Replacement of the enzymes lacking in Tay–Sachs disease (TSD) using adeno-associated virus gene therapy via both the thalamus and cerebrospinal fluid (CSF) is possible and potentially efficacious in humans, shows a study in Nature Medicine.

Lire >

14 mars 2022

Allogeneic mesenchymal stromal cell transplantation may be a feasible approach for SSc

A single infusion of allogeneic bone marrow-derived mesenchymal stromal cells (MSCs) was well tolerated and showed preliminary efficacy for severe diffuse systemic sclerosis (SSc) in a phase 1/2 proof-of-concept study by Dominique Farge (Hôpital St-Louis, Paris, France) and colleagues.

Lire >

7 mars 2022

Cemiplimab OS advantage demonstrated for recurrent cervical cancer

The EMPOWER-Cervical 1 trial findings demonstrate a significant survival advantage with cemiplimab versus investigator’s choice of chemotherapy for women with recurrent or metastatic cervical cancer that has progressed after treatment with platinum-containing chemotherapy.

Lire >

28 février 2022

BDNF Val66Met modifies outcomes in dominantly inherited Alzheimer’s disease

The Val66Met polymorphism of the brain-derived neurotrophic factor gene (BDNF) may be “an important moderator” of clinical and tau outcomes in people with dominantly inherited Alzheimer’s disease (DIAD), say researchers.

Lire >

21 février 2022

COVID-19 mitigation strategies reduced hospital admissions for childhood infections

UK researchers have found marked reductions in hospital admissions for a wide range of common and severe childhood infections in England in the 12 months after the start of the COVID-19 pandemic.

Lire >

14 février 2022

All-trans retinoic acid plus arsenic trioxide ‘noninferior’ to chemotherapy-based regimen

Findings from The Children’s Oncology Group AAML1331 study suggest that all-trans retinoic acid (ATRA) and arsenic trioxide may be able to reduce or eliminate the need for cytotoxic chemotherapy in children and young adults with a new diagnosis of acute promyelocytic leukaemia (APL).

Lire >

Pages